Evidence map›Paper›PMID 35640397›Full record

ArticleLeukemia research2022

ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia.

Swagata Goswami, Chi-Ling Chiang, Kevan Zapolnik, Jessica Nunes, Ann Ventura, Xiaokui Mo, Zhiliang Xie, L James Lee, Sivasubramanian Baskar, Christoph Rader and 4 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Nanotechnology boosts the efficiency of tumor diagnosis and therapy.Frontiers in bioengineering and biotechnology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Swagata GoswamiComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; Molecular, Cellular and Developmental Biology Graduate Program, The Ohio State University, Columbus, OH, USA.
Chi-Ling ChiangComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Kevan ZapolnikComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Jessica NunesComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; Molecular, Cellular and Developmental Biology Graduate Program, The Ohio State University, Columbus, OH, USA.
Ann VenturaComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Xiaokui MoDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA.
Zhiliang XieComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
L James LeeDepartment of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA.
Sivasubramanian BaskarNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Christoph RaderThe Scripps Research Institute, Jupiter, FL, USA.
John C ByrdComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA.
Mitch PhelpsComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; College of Pharmacy, The Ohio State University, Columbus, OH, USA.
Bhavana BhatnagarDepartment of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA.
Natarajan MuthusamyComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA. Electronic address: raj.muthusamy@osumc.edu.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
SPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 2009 to 2013
$11.2M
Targeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6M
Phosphatase activation as therapeutic strategy for Chronic lymphocyic leukemiaR01CA197844 · NCI · OHIO STATE UNIVERSITY · PI MUTHUSAMY, NATARAJAN, PHELPS, MITCH A · 2015 to 2019
$2.2M
Dietary Regulation of Colon Cancer MetastasisK00CA245813 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GOSWAMI, SWAGATA · 2021 to 2023
$283k
Protein Phosphatase PP2A and DNA damage in cell fate decisions of acute myeloid leukemic cellsF99CA245813 · NCI · OHIO STATE UNIVERSITY · PI GOSWAMI, SWAGATA · 2019 to 2020
$77k
NCI NIH HHS F99 CA245813NCI NIH HHS K00 CA245813NCI NIH HHS P30 CA016058NCI NIH HHS P50 CA140158NCI NIH HHS R01 CA197844NCI NIH HHS R35 CA197734
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Burkitt LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansPropylene GlycolsReceptor Tyrosine Kinase-like Orphan ReceptorsSphingosineTranslocation, GeneticOSU-2SPropylene GlycolsReceptor Tyrosine Kinase-like Orphan ReceptorsROR1 protein, humanSphingosine

Identifiers

PMID35640397
PMCPMC10029232

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.